

Rev03 Update: Dec,14,2021

## DATASHEET

## FGF-8e, Human

Cat. No.: Z03299

## **Product Introduction**

Human
Expressed with an N-terminal Met.
FGF-8e (Gln23-Arg233) Accession # P55075
> 95% as analyzed by SDS-PAGE
< 0.2 EU/µg of protein by gel clotting method
$ED_{50}$ < 2.5 $\mu g/ml$ in the presence of 1.0 $\mu g/ml$ heparin, measured in a cell proliferation assay using 3T3.
E. coli
~24.3 kDa, on SDS-PAGE under reducing conditions.
Lyophilized after extensive dialysis against PBS.
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH <sub>2</sub> O or PBS up to 100 $\mu$ g/ml.
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

## Background

**Target Background :** Fibroblast Growth Factor 8e (FGF-8e) is a cytokine belonging to the heparin-binding FGF family, which has at least 23 members. FGF-8 has 8 different isoforms, named FGF-8a through FGF-8h. Different FGF-8 isoforms have different receptor affinities, and thus participate in different signaling cascade pathways. FGF-8 has widespread expression during embryonic development, promoting gastrulation, somitogenesis, morphogenesis, and limb formation. FGF-8 also has oncogenic potential. While in normal cells FGF-8 is expressed at very low levels, in breast, prostate and ovarian cancer FGF-8 is highly expressed.FGF-8 promotes tumor angiogenesis by increasing neovascularization, and inducing osteoblastic differentiation.

Synonyms: Fibroblast Growth Factor-8; FGF-8e; AIGF; HBGF-8



For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.